期刊文献+

胃癌HER-2及Survivin蛋白表达与临床病理的相关性 被引量:2

Correlation of expression of HER-2 and survivin with clinical pathology in gastric cancer patients
原文传递
导出
摘要 目的观察表皮生长因子受体2(HER-2)及凋亡抑制蛋白Survivin在胃癌组织中的表达,探讨其与临床病理的相关性及其临床意义。方法使用免疫组织化学法检测2002-2011年江苏盛泽医院79例未经放、化疗的胃癌患者组织中HER-2及Survivin蛋白的表达。并分析两者与胃癌患者临床病理学参数之间的关系。结果 79例胃癌患者,男女比例为2.59:1,中位年龄为67岁,HER-2蛋白在胃癌中的阳性表达与肿瘤分化程度、Lauren分型、淋巴结转移及临床分期相关(p<0.05),与性别、年龄、肿瘤直径、浸润深度不相关。Survivin与肿瘤分化程度相关(p<0.05),与性别、年龄、肿瘤直径、Lauren分型、浸润深度、淋巴结转移及临床分期不相关。HER-2在Survivin阳性的表达率(70.59%)明显高于在Survivin阴性表达组(9.09%()P<0.05)结论胃癌HER-2蛋白的阳性表达与肿瘤分化程度、Lauren分型、淋巴结转移及临床分期相关,可用于指导临床用药;Survivin表达可作为判断胃癌恶性程度和预后的重要指标,其与HER-2表达正相关,可促进胃癌细胞增殖。 Objective To observe the expression of human epidermal growth factor receptor 2(HER-2) and inhibitor of apoptosis protein (survivin) in gastric cancer tissue and analyze the correlation of expression and the clinical pathology. Methods Immunohistochemistry assay was used for detection of HER2 and survivin protein expression in 79 cases without radiotherapy and chemotherapy for gastric cancer patients from 2002 to 2011 in the Shengze Branch of Jiangsu Province Hospital.. XI--test was used to analyze the relationship between HER-2 and survivin expression with clinical pathological parameters and significance. Results In 79 gastric cancer patients, the male and female ratio was 2.59:1, while the median age was 67 years old. The expression of HER-2 expression was correlated with tumor differentiation, Lauren typing, lymph node metastasis and clinical staging, but not with sex, age, the diameter of tumor and depth Of invasion. Survivin was correlated with tumor differentiation, but not with sex, age, the diameter of tumor, Lauren typing, depth of invasion, lymph node metastasis and clinical staging. Correlation analysis of HER2 and survivin expression, HER2 was significantly higher in positive expression rate of survivin (70.59%) than in group negative for survivin (9.09%,p〈0.05). Conclusion The positive expression of HER2 protein in gastric cancer correlates with tumor differentiation, Lauren typing, lymph node metastasis and clinical staging, so that it may guide the clinical treatment and improve the survival rate of patients. The expression of survivin is important for judging the malignancy and prognosis and it correlates with the expression HER2 and promotes the proliferation of gastric cancer cells
出处 《中国热带医学》 CAS 2012年第12期1516-1518,共3页 China Tropical Medicine
关键词 胃肿瘤 HER-2 SURVIVIN 免疫组织化学 Gastric tumor HER-2 Survivin Immnohistorochemistry
  • 相关文献

参考文献6

  • 1Kamanger F,Dores GM,Anderson WF. Patterns of cancer incidence,mortality,and prevalence across five continents:definging priorities to reduce disparities in different geographic regions of the world[J].Journal of Clinical Oncology,2006,(14):2137-2150. 被引量:1
  • 2胃癌HER2检测指南[J].中华病理学杂志,2011,40(8):553-557. 被引量:97
  • 3史忠新,王彩芹,贺颖.Survivin及P53在胃癌组织中表达相关性分析[J].中国热带医学,2007,7(2):191-192. 被引量:1
  • 4Im SA,Lee KE,Nam E. Potential prognostic significance of p185(HER2)overexpression with loss of PTEN expression in gastric carcinomas[J].Tumori,2005,(06):513-521. 被引量:1
  • 5Altieri DC. Survivin versatile modulation of cell division and apoptosis in cancer[J].Oncogene,2003.8581-8598. 被引量:1
  • 6Sarela AI,Macadam RC,Farmery SM. Expressin of the anti-apoptosis gene,survivin,predicts death form recurrent colorctal carcinoma[J].Gut,2000,(05):645-650. 被引量:1

二级参考文献17

  • 1李凤朝,孔庆兖,杨雪梅.Survivin在胃癌中的表达及其与细胞凋亡、p53的关系[J].实用肿瘤学杂志,2004,18(6):451-453. 被引量:8
  • 2张建娜,刘倩.胃癌组织中Survivin和Ki-67的表达及其临床意义[J].胃肠病学和肝病学杂志,2004,13(6):605-608. 被引量:9
  • 3Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase Ilalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol, 2005, 16(2) :273-278. 被引量:1
  • 4Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 2008, 19 (9) : 1523-1529. 被引量:1
  • 5Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer, 2009, 100 ( 3 ) :487-493. 被引量:1
  • 6Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 ( HER2 )-positive advanced gastric cancer ( GC ). J Clin Oncol, 2009, 27 : 18S( suppl : abstr LBA4509 ). 被引量:1
  • 7Bang Y J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742) :687-697. 被引量:1
  • 8Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 2008, 52(7) :797-805. 被引量:1
  • 9Ruschoff J, Nagelmeier I, Baretton G, et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe, 2010, 31 ( 3 ) :208-217. 被引量:1
  • 10RuschoffJ, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch, 2010, 457 ( 3 ) : 299-307. 被引量:1

共引文献96

同被引文献15

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部